Evidence map›Paper›PMID 40980396›Full record

ArticlePakistan journal of medical sciences2025

An experience with the use of Misoprostol in second trimester miscarriages, in women with prior cesarean births.

Nazia Liaqat, Qudsia Qazi, Fazeela Gul

Abstract read
In one paragraph

Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nazia LiaqatDr. Nazia Liaqat, MBBS, FCPS (Obstetrics & Gynecology) Associate Professor, Department of Gynecology, Medical Teaching Institute, Lady Reading Hospital, Peshawar, Pakistan.
Qudsia QaziDr. Qudsia Qazi, MBBS, FCPS (Obstetrics & Gynecology) Associate Professor, Department of Gynecology, Medical Teaching Institute, Lady Reading Hospital, Peshawar, Pakistan.
Fazeela GulDr. Fazeela Gul, MBBS FCPS II, Resident, Department of Gynecology, Medical Teaching Institute, Lady Reading Hospital, Peshawar, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To determine the success rate, frequency of complications and, side effects of misoprostol used, for second-trimester miscarriages, in women with history of previous cesarean section. Methodology: This cross sectional study was done at Lady Reading Hospital, Peshawar, from January 2021 to December 2022.The sample included 90 women, with a history of previous one cesarean section, undergoing medical management of second-trimester miscarriage. Outcomes noted were, success rate, frequency of scar complications and side effects. Results: The mean age of sample of 90 patients, was 28.87±4.6. The mean induction to expulsion time was 11 hours ± 3.9. Complete expulsion was achieved in 67.7% (61/90) cases. The need for surgical evacuation of retained products of conception, was observed in 32.5% (29/90) of cases. Scar complications were noted in 2.2% (2/90) cases. The need for surgical evacuation was more common with the vaginal route of administration as compared to the sublingual route i.e. 50% (20/40) vs 18% (09/50), p-0.001. Diarrhea was significantly associated with sublingual route of administration, p-0.001. Fever was common with the vaginal route, 47.5% (19/40) vs 26% (13/50), p-0.03. The mean induction to termination time was significantly shorter in the sublingual route group. (p-0.001). Conclusion: Misoprostol successfully and safely concludes the process of second trimester miscarriage in carefully selected women with a history of previous one cesarean birth.

Indexed as

MisoprostolMissed miscarriagePrevious cesarean section

Identifiers

PMID40980396
PMCPMC12444128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.